Intra-Cellular Therapies Reports Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intra-Cellular Therapies Reports Third Quarter 2014 Financial Results and Provides Corporate Update

NEW YORK, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the third quarter ended September 30, 2014, and provided a corporate update.

Selected Third Quarter 2014 Financial Results

The Company reported a net loss of $6.4 million, or $(0.22) per share (basic and diluted), for the third quarter of 2014 compared with a net loss of $4.9 million, or $(0.28) per share (basic and diluted), for the third quarter of 2013.

Research and development (R&D) expenses for the third quarter of 2014 were $4.0 million, compared to $4.2 million for the third quarter of 2013. The decrease of $0.2 million is due to a decrease of costs associated with clinical trials of ITI-007 that were completed in late 2013, with no related costs incurred in 2014 and is partially offset by expenses of approximately $1.3 million relating to manufacturing and other non-clinical costs relating to the testing of our ITI-007 product candidate, $0.6 million associated with our ITI-007-200 Phase 1/2 clinical trial in healthy geriatric and dementia patients, and $0.8 million of stock option expense due to stock options granted in 2014.

General and administrative (G&A) expenses were $2.6 million for the third quarter of 2014, compared to $1.3 million for the third quarter of 2013. The increase of $1.3 million is primarily due to stock option expense related to stock options granted in 2014, professional fees, directors' and officers' insurance costs, and board of director compensation fees, which are primarily related to the activities associated with being a public company, and to a much lesser extent additional personnel expenses.

Cash and investments totaled $136.0 million at September 30, 2014, compared to $37.2 million at December 31, 2013. The increase is due to the Company raising net proceeds of approximately $115.4 million in a public offering of its common stock during the first quarter of 2014.

The Company expects that existing cash and investments will be dedicated primarily to the ITI-007 clinical platform and pre-clinical activities. To a much lesser extent, funds will be used for other development programs the Company is undertaking, including our phosphodiesterase (PDE) programs.

Recent and Upcoming Corporate Highlights

  • The ITI-007 Phase 3 program has commenced and the Company expects to initiate patient enrollment in the first Phase 3 trial in schizophrenia later this month.
  • The Company continues to make progress with the preclinical development program for a long-acting injectable formulation of ITI-007 with the objective of entering the clinic in 2016.
  • The Company reported initial safety and tolerability data from the ITI-007-200 trial in healthy geriatric subjects at the recent American Neurological Association annual meeting. Additional data including the cohort of patients with dementia will be presented at the 7th Clinical Trials Conference on Alzheimer's Disease (CTAD) in Philadelphia, November 20-22, 2014.
  • The Company and Takeda announced the mutual termination of the collaboration to develop PDE inhibitors for CNS disorders, allowing ITI to regain worldwide rights to PDE1 inhibitor compounds previously licensed to Takeda.
  • The Company began patient enrollment in an open-label Phase 2 positron emission tomography (PET) clinical trial of ITI-007. The objective of this study is to further characterize the profile of ITI-007 in the brain of patients with schizophrenia, which the Company believes will highlight additional differentiating features of ITI-007 mechanisms.

"We continue to make significant progress on the development of our CNS platform including the development of ITI-007 for the treatment of psychiatric and neurological disorders. We look forward to 2015 to report results from our first Phase 3 clinical trial in patients with schizophrenia, as well as advance additional indications including the treatment of behavioral disturbances in patients with dementia, including Alzheimer's disease," said Dr. Sharon Mates, Chairman and CEO of ITI. "Behavioral disturbances in patients with dementia, including aggression, agitation, sleep disturbances and depression, significantly impact the lives of patients, family members and caregivers. We believe ITI-007 has the potential to safely and effectively treat these behaviors and improve patient quality of life and the lives of their families and caregivers."

Conference Call and Webcast Details

The Company will host a live conference call and webcast today at 8:30 AM Eastern Time to discuss the Company's financial results and provide a general business update. The live webcast and subsequent replay may be accessed by visiting the Company's website at www.intracellulartherapies.com . Please connect to the Company's website at least 5-10 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call 1-844-835-6563 (U.S.) or 1-970-315-3916 (international) to listen to the live conference call. The conference ID number for the live call is 25568442. Please dial in approximately 10 minutes prior to the call. The webcast will be available on the Company's website for seven days.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia. This study showed a statistically significant improvement in symptoms associated with schizophrenia at the 60 mg dose on the trial's pre-specified primary endpoint and a favorable safety profile. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders.  ITI-214 has finished several Phase 1 clinical trials and has been demonstrated to be safe and well-tolerated. The Company is also developing inhibitors against additional targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our expected use of our cash and cash equivalents and investments; our clinical development plans for ITI-007 under the caption "Recent and Upcoming Corporate Highlights;" and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for development and commercialization of our product candidates; and the other risk factors discussed under the heading "Risk Factors" contained in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the SEC. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

INTRA-CELLULAR THERAPIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
         
         
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
         
         
         
Revenues  $124,414 $667,955 $511,439 $1,909,471
         
Costs and expenses:        
Research and development    4,046,335  4,157,742  9,585,336  16,897,903
General and administrative    2,581,685  1,295,571  6,615,756  3,245,585
Total costs and expenses    6,628,020  5,453,313  16,201,092  20,143,488
         
Loss from operations    (6,503,606)  (4,785,358)  (15,689,653)  (18,234,017)
Interest expense   —    (131,888)  (7,073)  (607,960)
Interest income   88,099  5,626  204,396  11,589
Net loss   $ (6,415,507)  $ (4,911,620)   $ (15,492,330)  $ (18,827,388)
         
Net loss per common share:        
Basic & Diluted   $ (0.22)  $ (0.28)   $ (0.55)  $ (1.21)
         
Weighted average number of common shares:        
Basic & Diluted  29,379,156 17,527,774 28,386,794 15,616,835

The condensed consolidated statements of operations for the quarters ended September 30, 2014 and 2013 have not been audited and do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

INTRA-CELLULAR THERAPIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
     
     
  September 30, December 31,
  2014 2013
  (Unaudited) (Audited)
     
Assets    
Current assets:    
Cash and cash equivalents  $68,915,333 $35,150,924
Investment securities, available-for-sale  67,066,729 2,000,000
Accounts receivable  124,414 336,318
Prepaid expenses and other current assets  1,374,378 762,243
Total current assets  137,480,854 38,249,485
Property and equipment, net  57,440 68,272
Other assets  70,944 131,555
Total assets  $137,609,238 $38,449,312
     
Liabilities and stockholders' equity    
Current liabilities:    
Accounts payable  $503,882 $3,395,067
Accrued and other current liabilities   2,143,756  2,611,091
Accrued employee benefits   929,963  827,879
Total current liabilities   3,577,601  6,834,037
     
Stockholders' equity:    
Common stock, $.0001 par value: 100,000,000 shares authorized; 29,397,169 and 22,159,446 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively   2,940  2,216
Additional paid-in capital   207,152,913  89,177,556
Accumulated deficit   (73,056,827)  (57,564,497)
Accumulated other comprehensive loss   (67,389)  — 
Total stockholders' equity   134,031,637  31,615,275
Total liabilities and stockholders' equity  $137,609,238 $38,449,312

The condensed consolidated statements of operations for the quarters ended September 30, 2014 and 2013 have not been audited and do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns/Angeli Kolhatkar (Investors) Justin Jackson (Media) Phone: 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 0

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 159

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 40

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 255

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 0

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Join the Excitement of the Salt Lake Winter Roundup Event

Updated Category News Views 543

Join the Excitement of the Salt Lake Winter Roundup Event Get ready for a fantastic celebration at the Salt Lake Winter Roundup, an event that promises to be a highlight of the winter season. This all-day festival, taking place on Saturday, February 8, 2025, is set to invigorate downtown Salt Lake with an array of activities and cultural events celebrating the area's rich...

Continue Reading
Statkraft's Strategic Moves Lead to NOK 13.5 Billion Sale

Updated Category News Views 238

Statkraft Reports on Key Asset Divestment Statkraft experienced a notable shift in its operations with a significant divestment reported recently. The company's results in the third quarter demonstrated a decline despite increased power production. This downturn was linked to several factors, including low market prices and reduced contributions from its commercial market...

Continue Reading
Unlocking Wealth: Understanding TE Connectivity's Growth Journey

Updated Category News Views 218

Transforming Investment: The Growth of TE Connectivity TE Connectivity (NYSE: TEL) has shown remarkable performance in the stock market, significantly outpacing the broader market indices over the past fifteen years. With an impressive annual return of 13.74%, this company has established itself as a strong contender in the tech and connectivity industries. Investment...

Continue Reading
Hyperlink InfoSystem Leads California's Software Innovation

Updated Category News Views 128

Hyperlink InfoSystem's Impact on California's Tech Scene In the heart of innovation, California continues to be a significant player in the tech industry, home to numerous landmark companies that shape the future of technology. As digital transformation accelerates across industries, the demand for proficient software development partners has never been so urgent....

Continue Reading
Sola Security Secures $35 Million to Transform Cybersecurity

Updated Category News Views 197

Sola Security's Innovative Funding Round Sola Security, an emerging leader in cybersecurity AI, has made headlines by raising $35 million in a recent Series A funding round. This investment follows their successful $30 million seed round earlier, bringing the total funds raised to a remarkable $65 million. The company plans to use these new resources to further enhance...

Continue Reading